Le Gars M, Sadoff J, Cardenas V, Heerwegh D, et al. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial. Vaccine 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
PMID: 38918103